ArticleKidney medicine2026
A Case Series of Elevated Donor-Derived Cell-Free DNA Leading to Diagnosis of Posttransplant Glomerulonephritis.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
No prior associations between elevated donor-derived cell-free DNA (dd-cfDNA) levels and glomerulonephritis in kidney transplant recipients have been reported. We present 3 cases of posttransplant glomerulonephritis diagnosed in patients by allograft biopsy performed due to elevated dd-cfDNA who maintained baseline serum creatinine and showed no significant change in urinalysis parameters. Case 1 showed C3 glomerulopathy likely related to monoclonal gammopathy in a patient whose native kidney disease was biopsy-proven focal segmental glomerulosclerosis; case 2 showed membranoproliferative glomerulonephritis likely associated with untreated prostate adenocarcinoma in a patient whose native kidney disease was autosomal dominant polycystic kidney disease; and case 3 showed recurrent IgA nephropathy. There was no evidence of rejection in any of the cases, and all patients had improvement in dd-cfDNA levels with treatment of the underlying/associated conditions. These cases highlight the utility of dd-cfDNA obtained during routine transplant monitoring in detecting allograft injury that is not related to rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.